Schedule II, III, or V classifications apply to codeine in the United States depending on the formulation under the federal Controlled Substances Act. Your liver converts roughly 5 to 10 percent of every dose into morphine, which creates real risks of tolerance, physical dependence, and respiratory depression at higher intake. Even low-dose cough syrups now sit behind the pharmacy counter or require a prescription in most states.
This guide walks through how federal scheduling works for codeine, where each formulation lands on the ladder, and how state rules can tighten access further.
The Opioid at the Center of a Federal Scheduling System
Every controlled drug in the U.S. gets sorted by the Drug Enforcement Administration under the Controlled Substances Act (CSA), a federal law first passed in 1970. Schedule I carries the tightest restrictions and no accepted medical use, so that tier is never prescribed. Schedules II through V loosen in stages as medical value rises and abuse potential drops.
Codeine itself is a naturally occurring opioid derived from morphine, which comes from the opium poppy. Once it reaches your brain, codeine binds to the same opioid receptors as stronger painkillers like oxycodone and fentanyl, but with far less intensity. That weaker receptor activity is why prescribers have used it for decades as a medication for mild to moderate pain and as a cough suppressant in low-dose syrups.
Why “Natural” Does Not Mean “Safe”
Codeine’s plant origin often convinces people that the drug sits closer to aspirin than to oxycodone. The evidence runs the other way. Your liver converts 5 to 10 percent of any codeine dose into morphine through a standard metabolic pathway, and that morphine drives the pain relief, the sedation, and the slowed breathing that becomes dangerous at high intake. Any substance that triggers that pathway gets treated as a regulated drug by federal authorities.
Why Codeine Earned Its Place on the Controlled List
The liver’s conversion of codeine into morphine is the single biggest reason the drug sits on the controlled list. Regular users then build tolerance and physical dependence, which means your body adapts to the substance and reacts with withdrawal symptoms when it disappears. Withdrawal can include muscle aches, insomnia, nausea, and anxiety, and it pushes some users toward higher doses that raise the risk of respiratory depression.
Historical abuse patterns sealed the regulatory case. Reports of codeine misuse stretch back decades, and combination products like Tylenol with Codeine became some of the most diverted prescription painkillers in the United States before tighter rules arrived. The World Health Organization has also flagged codeine products as a global concern when sold without prescription oversight, which is why pharmacies now treat those products with extra care.
Clearing Up the “Weaker Opioid” Myth
Potency measures how much of a drug is needed to produce an effect, not how dangerous the drug can be in absolute terms. Codeine is weaker than oxycodone milligram for milligram, yet a high enough dose still produces the same respiratory depression risk as stronger opioids. The FDA has issued multiple safety communications about codeine use in children because that weaker reputation led to overdoses families did not see coming.
That same loose reputation in pediatric care is exactly why the federal government sorts codeine products into different schedules in the first place.
Federal Schedules That Apply to Different Codeine Formulations
Codeine is unusual among opioids because it lands on three different schedules rather than one. The schedule depends entirely on how the drug is formulated and what other active ingredients share the tablet or syrup you receive.
| Schedule | Typical Formulation | Common Use |
|---|---|---|
| Schedule II | Pure codeine phosphate or codeine sulfate tablets | Prescription-strength pain management in clinical settings |
| Schedule III | Codeine combined with acetaminophen, aspirin, or similar non-opioid painkillers (commonly 15 to 90 mg of codeine per unit) | Outpatient pain relief, historically the dominant combination product |
| Schedule V | Low-dose codeine cough syrups (generally 10 mg or less per dosage unit, often paired with a non-opioid expectorant) | Cough suppression with the lightest federal restrictions |
Schedule II treats codeine the same as oxycodone and morphine for prescription purposes, including tight rules on refills and written prescriptions. Schedule III products follow a more relaxed prescription pathway but still require medical authorization. Schedule V sits at the bottom rung, and in some states those cough preparations can technically be sold without a prescription, a setup that looks loose on paper and tightens sharply in practice.
Why One Drug Lands in Three Categories
The DEA splits codeine across schedules to match the real-world abuse risk of each formulation. Pure codeine at high strength carries the most danger and earns Schedule II. Pairing codeine with acetaminophen caps how much you can safely take, which lowers the abuse ceiling and drops the combination to Schedule III. Cough syrups contain so little codeine per dose that the federal system tucks them into Schedule V, the lightest tier for any regulated opioid.
Those federal tiers only tell part of the story, because state legislatures frequently redraw the lines around them.
How State Laws Reshape the Federal Schedule for Codeine
Federal scheduling sets the floor, but state laws can build a higher ceiling. Several states have moved certain codeine products into stricter categories than the federal system requires, especially Schedule V cough syrups. In roughly half of U.S. states, a low-dose codeine cough preparation that the DEA allows to be sold behind the pharmacy counter now requires a full prescription.
States that have tightened codeine access include large markets like California, Texas, New York, and Florida, along with many smaller jurisdictions that followed the same path after seeing local abuse patterns. The practical effect is that a product legal at the federal level becomes effectively unavailable without a doctor’s visit once state law reclassifies it.
The Hydrocodone Rescheduling Precedent
Hydrocodone combination products offer a useful parallel. Those products once lived in Schedule III next to codeine combinations, but the DEA moved hydrocodone combinations into Schedule II in 2014 after years of abuse data. Many regulators and clinicians read that move as a signal for codeine: if abuse patterns or overdose data shift, federal authorities can and do reschedule drugs even when the medical community has used them for generations.
That federal reshuffling power rarely touches patients directly, though, since prescription writing, pharmacy checks, and possession caps govern everyday encounters.
Prescription Rules, Pharmacy Oversight, and Possession Limits
Every schedule that includes codeine carries a prescription requirement, though the strictness of that requirement scales with the schedule. Schedule II codeine demands a written or electronic prescription with no refills, while Schedule III products allow a limited number of refills under federal rules. Schedule V products can sometimes be dispensed without a prescription in states that still allow it, but the pharmacist must verify your identity and document the sale.
DEA Registration and Pharmacy Duties
Every pharmacy must hold an active DEA registration and follow detailed recordkeeping rules before dispensing codeine. Every codeine transaction gets logged, stored securely, and audited, and prescribers must also hold their own DEA registration before writing a codeine prescription. That dual registration system is what makes codeine impossible for you to buy casually in the United States, even in states where Schedule V sales technically survive.
Possession and Sharing Rules Worth Knowing
Possessing codeine without a valid prescription in your name counts as unauthorized possession under federal law, and the same rule applies to leftover medication after a surgery or a dental visit. Giving a codeine tablet to a family member, even with good intentions, turns a legal prescription into an illegal transfer. Travel adds another layer: carrying codeine across state lines or international borders without proper documentation can trigger charges in both the origin and destination jurisdictions.
Penalties for Possessing Codeine Without a Prescription
Federal penalties scale with the schedule and the amount involved. Simple possession of a Schedule III or V codeine product without a prescription is a misdemeanor under federal law and can bring up to one year in prison plus fines for a first offense. Possession of Schedule II codeine, or any codeine product with intent to distribute, can bring felony charges with sentences measured in years rather than months.
How State Charges Stack on Top
State charges often hit harder than federal ones. Many states classify unauthorized possession of codeine as a felony regardless of schedule, with possible prison sentences that exceed the federal range for the same conduct. Possession near a school, on government property, or in combination with other controlled substances can trigger enhanced penalties on both the state and federal side, and probation violations can revive old sentences in some cases.
Distribution or intent to sell is treated as a separate, more serious crime than simple personal possession. Even a small number of tablets handed to a friend can be charged as distribution, which dramatically increases your legal exposure and the potential prison time.
Takeaways
Codeine is a federally controlled opioid in every form, from pure prescription tablets down to small-dose cough syrups. Federal scheduling splits the drug across three tiers based on formulation, state laws routinely tighten those tiers, and possession without a valid prescription carries real criminal risk at both the federal and state level.
Treat every codeine product as a regulated drug, keep it in a locked location, and never share it with anyone else, no matter how mild the dose looks on the label.
FAQ
What schedule is codeine classified as under federal law?
Codeine falls under Schedule II, Schedule III, or Schedule V depending on its formulation. Pure codeine used for pain management is Schedule II, codeine combined with acetaminophen or similar non-opioid painkillers is Schedule III, and low-dose codeine cough syrups sit in Schedule V.
Why is codeine considered a controlled substance?
Your liver converts codeine into morphine after ingestion, which creates real risks of physical dependence, tolerance, withdrawal symptoms, and respiratory depression. Those risks, combined with decades of documented abuse patterns, place codeine under the federal Controlled Substances Act.
Do all codeine-containing medications require a prescription?
You need a prescription for any Schedule II or III codeine product in every U.S. state, and many states also require a prescription for Schedule V cough syrups that federal law allows to be sold without one. When in doubt, assume a prescription is required.
Is codeine an opioid?
Yes. Codeine is a naturally occurring opioid derived from morphine, and it binds to the same opioid receptors in your brain as oxycodone and fentanyl, just with weaker intensity. That opioid activity is one reason federal authorities place it under the Controlled Substances Act.
What is the difference between Schedule III and Schedule V codeine products?
Schedule III covers codeine combined with acetaminophen, aspirin, or similar non-opioid painkillers at 15 to 90 mg per unit, used for outpatient pain relief. Schedule V covers low-dose codeine cough syrups at roughly 10 mg or less per dosage unit, paired with a non-opioid expectorant for cough suppression.
How does state law affect codeine’s controlled substance status?
State laws can place codeine products into stricter categories than federal rules require. Roughly half of U.S. states now require a full prescription for Schedule V cough syrups that the DEA would otherwise allow to be sold behind the pharmacy counter, and states like California, Texas, New York, and Florida have led that tightening.
